Last reviewed · How we verify
ARRY-403, glucokinase activator; oral
Glucokinase activator
Glucokinase activator Used for Type 2 diabetes.
At a glance
| Generic name | ARRY-403, glucokinase activator; oral |
|---|---|
| Sponsor | Array BioPharma |
| Drug class | Glucokinase activator |
| Target | Glucokinase |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 1 |
Mechanism of action
Activates glucokinase, an enzyme involved in glucose metabolism, to improve glycemic control.
Approved indications
- Type 2 diabetes
Common side effects
Key clinical trials
- A Safety Study of ARRY-403 in Patients With Type 2 Diabetes (PHASE1)
- A Safety Study of ARRY-403 in Patients With Type 2 Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARRY-403, glucokinase activator; oral CI brief — competitive landscape report
- ARRY-403, glucokinase activator; oral updates RSS · CI watch RSS
- Array BioPharma portfolio CI